NCT02565147 - Bivalirudin Infusion for Ventricular Infarction Limitation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 19, 2014

Primary Completion Date

June 14, 2016

Study Completion Date

June 14, 2016

Conditions

Acute Myocardial Infarction

Interventions

PROCEDURE

PPCI

PPCI for treatment of participants presenting with large STEMI.

DRUG

Bivalirudin

Bivalirudin is an anticoagulant that binds thrombin in a bivalent and reversible fashion and directly inhibits it.

DRUG

Heparin

Heparin is an anticoagulant.

Trial Locations (4)

Hospital Lariboisière, Paris

Hopital Ambroise Paré, Boulogne

VUMC Amsterdam, Amsterdam

Erasmus Medical Center, Rotterdam